Trial Profile

A Multi-center, Open-label, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AN9025 in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AN 9025 (Primary)
Indications Adenocarcinoma; Biliary cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic ductal carcinoma; Skin cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Adlai Nortye

12 Feb 2026 According to an Adlai Nortye media release, the first patient has been dosed in the United States in early February in its ongoing Phase 1 clinical trial of AN9025, a pan-RAS (ON) inhibitor.
11 Feb 2026 Status changed from not yet recruiting to recruiting.
29 Dec 2025 According to an Adlai Nortye media release, the company expects to initiate the phase I clinical study in Q1 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com